Jeff Geschwind, MD
Welcome to Dr. Jeff Geschwind's Official Website
Jeff Geschwind, is currently the Director of Oncology at USA Clinics Group; the Medical Director for Oncology, Image-Guided Therapy and Imaging Core Lab at NAMSA, one of the largest contract research organizations in the United States with offices in New York City; Medical Advisor (Medical Affairs) for HistoSonics, a company developing a non-invasive image-guided therapy for liver cancer and a consultant for Cage Pharma, previously PreScience Labs, a company he founded in 2009 which is focused on developing cancer drugs targeting tumor metabolism, specifically glycolysis. He is also a scientific consultant for Philips Healthcare advising them on all matters related to oncology and image-guided therapy.
Your destination for insights into the groundbreaking work and achievements of Dr. Jeff Geschwind, MD.
Dr. Geschwind developed an interest in medicine and science through his early love of biology. After having attended the University of Pennsylvania to ease his transition into a new life in the United States from France, he earned his medical degree from Boston University School of Medicine and completed his residency training in Diagnostic Radiology at the University of California at San Francisco as a Resident-Scholar sponsored by the National Institutes of Health (NIH) which allowed him to dedicate a year of his residency to research. During that year, he focused his research on cardiac magnetic resonance imaging, published many scientific manuscripts, earned his first research award and more importantly, learned how to manage and run a research laboratory. He then pursued his fellowship training in Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine before joining the faculty as an Assistant Professor. Shortly after, he was appointed the Director of the Division of Vascular and Interventional Radiology and a few years later, he was promoted to Professor of Radiology, Surgery, and Oncology at the Johns Hopkins University School of Medicine.
Pioneer in Oncology and Interventional Radiology
Dr. Jeff Geschwind is recognized internationally as a leader in liver cancer treatment and interventional oncology.
Under his leadership, the Division of Vascular and Interventional Radiology underwent massive growth, both in terms of clinical activities and research. He also helped plan and design the division’s expanded, state-of-the art facilities in the new clinical building where the division has resided since 2012.
Leadership in Medical Innovation
With pivotal roles at NAMSA, USA Clinics Group, and Philips Healthcare, Dr. Jeff Geschwind is driving advancements in oncology and medical technology.
As a physician, he concentrated his efforts on treating hepatic cancer and more generally, focused on the nascent field of Interventional Oncology, which he helped develop into a major new field of medicine. He founded the Center of Oncologic Interventions, which utilized revolutionary imaging technology in collaboration with Philips Health Care (partly supported by funding from the NIH) to visualize tumors, target them with exquisite precision and as a result treat them more effectively. After having received an RO1 grant from the NIH in 2005, he also established his research laboratory focusing on cancer therapeutics that specifically block tumor glycolysis in cancer cells. In 2008, he received a $1.4 million philanthropic donation to further support this research. In 2009, he founded a company based on this technology and has raised $5M towards the goal of starting Phase I clinical trials for liver and pancreas cancer. He is recognized worldwide as a key opinion leader in the field of liver cancer (hepatocellular carcinoma) and has received numerous foundation, industry and federal grants for his research in the field.
Transforming Cancer Care Worldwide
Explore Dr. Geschwind’s innovative contributions to minimally invasive, image-guided oncology procedures that redefine cancer treatment.
After 19 years at Johns Hopkins, Dr. Geschwind was recruited to Yale School of Medicine to become the Chairman of Radiology and Biomedical Imaging, Radiologist in Chief at Yale-New Haven Hospital and Professor of Radiology and Medicine (Oncology). While there, he created a new research laboratory dedicated to liver cancer and Interventional Oncology and received a major grant from the NIH for research on targeting and imaging of the tumor microenvironment. Dr. Geschwind is a highly experienced, talented and compassionate physician and extraordinary innovator. He has published almost 300 scientific manuscripts in the most highly-rated medical journals (Google Scholar H-index of 86 making him one of the most highly rated radiologist in the world and reflecting the high impact of his scientific publications), wrote the first textbook dedicated to Interventional Oncology -a new and exciting branch of medicine- and co-edited the textbook of reference in Interventional Radiology, namely, Abram’s Angiography, created a company based on a drug he discovered with his colleagues while on faculty at Johns Hopkins to treat cancer and treated clinically over 2000 patients afflicted by liver cancer in his career.